Clinical Pharmacokinetics in Organ Transplant Patients

Clinical Pharmacokinetics

Volumn 16, Issue 3, 1989, Pages 134-161

  Venkataramanan, Raman ^a   Habucky, Karen ^a   Burckart, Gilbert J ^a   Ptachcinski, Richard J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; CYCLOSPORIN DERIVATIVE;

CLINICAL ARTICLE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; BONE MARROW TRANSPLANTATION; HEART TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

AZATHIOPRINE; BONE MARROW TRANSPLANTATION; CYCLOSPORINS; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METHYLPREDNISOLONE; PHARMACOKINETICS; PREDNISOLONE; PREDNISONE;

EID: 0024477277     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198916030-00002     Document Type: Review

References (219)

1. Assessment of cyclosporin A in whole blood and plasma in five patients with different hematocrits
2. Evidence of a cyclosporine binding protein in human erythrocytes
3. Temperature dependent binding of cyclosporine to an erythrocyte protein
4. Cyclosporine metabolic disposition after oral administration in pretransplant end stage renal disease patients
5. 14-labelled hydrochlorothiazide in human beings
6. Sequential changes of plasma proteins after surgical trauma
7. Oral administration of cyclosporine A for recipients of allogenic marrow transplants: implications of clinical gut dysfunction
8. Blood and tissue distribution of cyclosporine in humans and mice
9. The effect of cyclosporine A on hepatic microsomal drug metabolism in rat
10. Serum immunosuppressive activity of azathioprine in normal subjects and patients with liver disease
11. Immunopharmacokinetics
12. Endogenous and exogenous glucocorticoids in Cushingoid patients
13. Effect of cardiac disease on pharmacokinetics
14. Pharmacokinetics in patients with cardiac failure
15. Malabsorption as a complication of congestive heart failure
16. Clinical pharmacokinetics of Ciclosporin A in bone marrow transplant patients
17. Protein binding and kinetics of drugs in liver disease
18. Prednisolone disposition and protein binding in oral contraceptive users
19. Nicardipine increases cyclosporin blood levels
20. Interaction of rifampin and glucocorticoids — adverse effect on renal allograft function
21. Impaired clearance of ceftizoxime and cefotaxime after orthotopic liver transplantation
22. Excretion of cyclosporine and its metabolites in human bile
23. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients
24. Cyclosporine
25. Cyclosporine absorption following orthotopic liver transplantation
26. Cyclosporine pharmacokinetic profiles in liver, heart and kidney transplant patients as determined by high performance liquid chromatography
27. The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts
28. Interaction between cyclosporine A and phenobarbital
29. Effect of rifampicin on cyclosporin A. Blood levels in a renal transplant recipient
30. The therapeutic use of azathioprine in renal transplantation
31. Does OKT3 monoclonal antibody react with an antigen recognition structure on human T cells
32. Pindolol availability in hypertensive patients with normal and impaired renal function
33. Kinetic analysis of d-xylose absorption in normal subjects and in patients with chronic renal failure
34. The effect of congestive heart failure on quinidine pharmacokinetics
35. Oral contraceptive interaction with cyclosporin
36. Early recovery of albumin synthesis after liver transplantation
37. Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients
38. Active drug metabolites and renal failure
39. The effect of uremia and kidney transplantation on the binding capacity of albumin
40. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
41. 6α methylprednisolone and 6α methylprednisone plasma protein binding in humans and rabbits
42. Potentiation by inhibition of drug degradation: 6 substituted purines and xanthine oxidase
43. Azathioprine
44. Prednisolone levels in the plasma and urine. A study of two preparations in man
45. Diurnal variation in prednisolone kinetics
46. Interaction of metronidazole with phenobarbital, Cimetidine, prednisone and sulfasalazine in Crohn’s disease
47. Role of bile and bile salts on cyclosporine absorption in dogs
48. Ketoconazole, cyclosporin metabolism and renal transplantation
49. The presence of cyclosporine in body tissues and fluids during pregnancy
50. Intravenous cyclosporine kinetics in renal failure
51. Evaluation of cyclosporin-phenytoin interaction with observation on cyclosporin metabolites
52. Estimation of transcortin concentration by measurements of plasma protein binding of prednisolone and by electroimmunodiffusion
53. Proteinurie nach Nierentransplantation
54. Pharmacokinetics of 3 prednisolone prodrugs — evidence of therapeutic inequivalence in renal transplant patients with rejection
55. Kinetics and dynamics of prednisolone
56. Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in Cushingoid and non-Cushingoid patients
57. Trough levels and concentration time curve of cyclosporine in patients undergoing renal transplantation
58. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation
59. Effects of renal disease: altered pharmacokinetics
60. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review
61. Prednisone and prednisolone bioavailability in renal transplant patients
62. Prednisolone disposition in Cushingoid and non-Cushingoid kidney transplant patients
63. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patients
64. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3
65. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis
66. Absorption of cyclosporine A after oral dosing
67. Pharmacokinetics of oral cyclosporin A (Sandimmune) in healthy subjects
68. Diazepam and lidocaine plasma protein binding in renal disease
69. Erythromycin enhances the absorption of cyclosporin
70. Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients
71. An acid metabolite of cyclosporine
72. Cyclosporine
73. Variation in plasma prednisolone concentrations in renal transplant recipients given enteric coated prednisolone
74. Inhibition of cyclosporine metabolism by other drugs in vitro
75. Reduced drug elimination in congestive heart failure. Studies using aminopyrine and model drug
76. A physicochemical approach to the intraluminal phase of fat absorption
77. Decreased first pass metabolizing of labetalol in chronic liver disease
78. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A
79. Drug disposition in liver transplant patients
80. Sensitive high performance liquid chromatographic analysis of vitamin E and vitamin A using ampherometric and ultraviolet detection
81. Drug binding proteins in liver transplant patients
82. Determinants of drug disposition in patients with cirrhosis
83. Ranitidine, Cimetidine and the cyclosporine treated patient
84. The effect of vehicle on the oral absorption of cyclosporine
85. Alterations of glucocorticoid actions by other drugs and disease states
86. Monitoring prednisone and prednisolone
87. Individualization of cyclosporine therapy — using pharmacokinetic and pharmacodynamic parameters
88. Pharmacokinetics of cyclosporine in human renal transplantation
89. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay
90. Analysis of pharmacokinetic profile in 232 renal and 87 cardiac allograft recipients treated with cyclosporine
91. Alterations in cyclosporine pharmacokinetics after renal transplantation are linked to rapid increases in hematocrit, lipoproteins and serum protein
92. The effect of roux-en-y biliary enterostomy on the absorption of cyclosporine: relevance to poor drug bioavailability in children after orthotopic liver transplantation
93. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation
94. The effect of food and cholestyramine on the absorption of cyclosporin in cardiac transplant recipients
95. Interaction between Phenytoin and cyclosporine following organ transplantation
96. Cyclosporine plasma levels in renal transplant patients
97. The effect of age and liver disease on the disposition and elimination of diazepam in adult man
98. Pharmacokinetics of procainamide in man
99. Effect of danazol on cyclosporine pharmacokinetics
100. Measurement of prednisolone and some of its metabolites in urine of patients after orthotopic liver transplantation as a means of monitoring prednisolone absorption
101. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects
102. Interaction of pancuronium and corticosteroids
103. Effect of somatostatin analog (SM5201-995) on cyclosporine levels
104. Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment
105. Inhibition of prednisolone metabolism by cyclosporine in kidney transplanted patients
106. Cyclosporin: measurement of fraction unbound in plasma
107. Saturable binding of cyclosporine A to erythrocyte. Estimation of binding parameters in renal transplant patients and implications for bioavailability assessment
108. Prednisolone clearance at steady state in man
109. Cyclosporine and tegretol — another drug interaction
110. Influence of blood components on the tissue uptake indices of cyclosporine in rats
111. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporine A in the blood
112. Azathioprine metabolism in kidney transplant recipients
113. Deposition of nine metabolites of cyclosporine in human tissues, bile, urine and whole blood
114. Effect of renal transplantation on protein binding of drugs in serum of donor and recipient
115. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients
116. The pharmacokinetics of cyclosporine A in uremic patients
117. Verapamil inhibits cyclosporin metabolism
118. The free fraction of cyclosporine in plasma. Clinical findings with a new method
119. Pharmacologic monitoring and the clinical use of cyclosporine
120. A safer approach to the clinical use of cyclosporine. The predose calculation
121. Clinical pharmacological observations on azathioprine in kidney transplant patients
122. Metabolism of cyclosporine
123. Disposition of cyclosporine in several animal species and man
124. Rifampin reduces effectiveness and bioavailability of prednisolone
125. Effect of bile on cyclosporine absorption in transplant patients
126. Antipyrine kinetics in liver disease and transplantation
127. Potency and duration of action of glucocorticoids — effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function
128. Toxicity of cyclosporine during treatment with androgens
129. The metabolism of 28 serum proteins in a human liver transplantation
130. Clinically important interaction of cyclosporine and erythromycin
131. Serum proteins after a liver transplant
132. Use of cyclosporine by constant rate infusion immediately after heart transplantation
133. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis
134. Cyclosporine pharmacokinetics in man
135. Distribution and binding of cyclosporine in blood and tissues
136. Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin
137. Plasma protein binding of Phenytoin and warfarin in patients undergoing renal transplantation
138. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients
139. Absolute bioavailability of digoxin in chronic renal failure
140. Morphine and Phenytoin binding to plasma proteins in renal and hepatic failure
141. Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation
142. Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver
143. Clinical pharmacokinetics of prednisone and prednisolone
144. Cyclosporin-diltiazem interaction
145. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding
146. Cyclosporine pharmacokinetics in children following cadaveric renal transplantation
147. Cyclosporine concentration determinations for monitoring and pharmacokinetic studies
148. Clinical pharmacokinetics of cyclosporine
149. Cyclosporine kinetics in healthy volunteers
150. Cyclosporine-high dose steroid interaction in renal transplant recipients: assessment by HPLC
151. Cyclosporine kinetics in renal transplantation
152. The effect of food on cyclosporine absorption
153. The binding of drugs to plasma proteins from patients with poor renal function
154. Cyclosporine pharmacokinetics in uremic patients. Influence of different assay methods
155. Therapeutic drug monitoring of cyclosporin: practical applications and limitations
156. Cyclosporine levels in human tissues of patients treated for one week to one year
157. Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients
158. Are clearance pathways impaired in patients with cyclosporine nephrotoxicity
159. The effect of cyclosporine on the pharmacokinetics of prednisolone in renal transplant patients
160. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal transplant patients
161. The plasma creatinine concentration is not an accurate reflection of the glomerular filtration rate in stable renal transplant patients receiving cyclosporine
162. Dose dependent pharmacokinetics of prednisone and prednisolone in man
163. Cyclosporin interaction with danazol and norethiderone
164. Increased alpha 1 acid glycoprotein and lidocaine disposition in myocardial infarction
165. Clearance concepts in pharmacokinetics
166. Cyclosporin-phenytoin interaction: reevaluation using metabolite data
167. 14
168. Critical issues in cyclosporine monitoring: report to the task force on cyclosporine monitoring
169. Plasma protein binding of furosemide in kidney transplant patients
170. Furosemide kinetics and dynamics after kidney transplant
171. Cyclosporine disposition in patients with liver disease
172. Accumulation of normeperidine (N) an active metabolite of meperidine (M) in patients with renal failure or cancer
173. Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine
174. Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans
175. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure
176. Furosemide kinetics in renal failure
177. Prednisone and prednisolone kinetics — observations after liver transplantation
178. Influence of biliary T-tube clamping on cyclosporine pharmacokinetics in liver transplant recipients
179. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats
180. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies
181. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine
182. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation
183. Cyclosporine pharmacokinetics in heart transplant patients
184. Conjugative drug metabolism in liver transplant patients
185. Cyclosporine and its metabolites in mother and baby
186. Extraction ratio of cyclosporine in a liver transplant patient with organ rejection
187. Cyclosporine bioavailability in liver disease
188. The clearance of cyclosporine by hemodialysis
189. Cyclosporine kinetics in liver disease
190. Biliary excretion of cyclosporine in liver transplant patients
191. Subtherapeutic cyclosporine concentrations during nafcillin therapy
192. Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome
193. Cyclosporine: structure, pharmacokinetics, therapeutic drug monitoring
194. The effect of oral metoclopramide on the absorption of cyclosporine
195. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient
196. Interaction of calcium blockers and cyclosporine
197. Cyclosporine metabolite concentrations in blood of liver, heart, kidney and bone marrow transplant patients
198. The adverse effect of anticonvulsant therapy on renal allograft survival
199. The variation in twenty one serum proteins before and after renal transplantation
200. The variation in twenty one serum proteins before and after renal transplantation. II. Changes during acute rejection
201. Albumin metabolism in patients after renal transplantation
202. Temperature dependency of apparent cyclosporin A concentrations in plasma
203. Influence of hepatic disease on pharmacokinetics
204. Drug administration in hepatic disease
205. The influence of cirrhosis on steady state blood concentrations of unbound propranolol after oral administration
206. Propranolol disposition in renal failure
207. Pharmacologic aspects of cyclosporine therapy: pharmacokinetics
208. Cyclosporine: pharmacokinetics, metabolism and drug interaction
209. Cyclosporine
210. Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients
211. Effect of obesity on cyclosporine disposition
212. Effect of age on cyclosporine kinetics in marrow transplant recipients
213. Blood protein binding of cyclosporine in transplant patients
214. Ranitidine does not influence the blood cyclosporin levels in renal transplant patients
215. Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells
216. Inhibition of first pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol